Physician

Svastijaya Daviratanasilpa, M.D.

According to 2025 Medicare claims, Svastijaya Daviratanasilpa, M.D. (NPI: 1720291404) practices nephrology in the Dover, DE market, with the plurality of this provider's patient population coming from Kent, DE. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES PA (NPI: 1407805203; TIN: 510123099) and primary practice location at 19713-2081.

Daviratanasilpa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 535 traditional Medicare patients, billed 8,717 HCPCS/CPT codes, and received $483,938 in Medicare payments. The top billing code was 36902 (Insertion of needle and/or tube into hemodialysis circuit and balloon dilation of dialysis segment with review by radiologist). Part D data shows 2,008 prescription claims across 309 beneficiaries totaling $614,351 in drug costs, led by Jardiance (Empagliflozin). DME data shows 104 claims. Open Payments data shows 44 records totaling $1,208. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $112,800 to $614,351. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	799	32,232	$797,024
2016	785	24,166	$748,672
2017	759	16,114	$645,020
2018	845	15,185	$633,068
2019	767	13,080	$647,233
2020	774	13,288	$677,502
2021	701	10,987	$596,826
2022	717	8,301	$540,077
2023	658	8,779	$515,773
2024	535	8,717	$483,938

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	174	945	$112,800
2016	189	937	$136,492
2017	190	860	$110,165
2018	204	1,028	$259,243
2019	232	1,063	$122,050
2020	224	1,165	$141,568
2021	232	1,360	$207,018
2022	254	1,509	$470,553
2023	301	2,039	$1,011,549
2024	309	2,008	$614,351

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	24	$1,398
2019	N/R	25	$1,268
2020	N/R	N/R	N/R
2021	N/R	24	$1,268
2022	N/R	11	$1,038
2023	N/R	81	$2,754
2024	N/R	104	$5,158

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
36902	Insertion of needle and/or tube into hemodialysis circuit and balloon dilation of dialysis segment with review by radiologist	102	140	$918
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	212	446	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	60	92	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	211	436	$13
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	151	4,481	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	175	12,350	$233,889
Farxiga	Dapagliflozin Propanediol	71	4,260	$74,315
Kerendia	Finerenone	37	2,460	$50,995
Lokelma	Sodium Zirconium Cyclosilicate	26	1,620	$35,227
Cinacalcet Hcl	Cinacalcet Hcl	12	900	$32,525

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	16	$3,536
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	16	$539
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	35	$414
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	20	$407
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	44	$1,208	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Svastijaya Daviratanasilpa, M.D.?

Tedicare shows public-source Medicare data for Svastijaya Daviratanasilpa, M.D. (NPI 1720291404), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Svastijaya Daviratanasilpa, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Svastijaya Daviratanasilpa, M.D.?

Svastijaya Daviratanasilpa, M.D. is linked to NEPHROLOGY ASSOCIATES PA (billing NPI 1407805203) in the available physician profile data.

Does Svastijaya Daviratanasilpa, M.D. have Open Payments data?

Svastijaya Daviratanasilpa, M.D. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.